Is BioCardia, Inc. (BCDA) a Buy, Sell, or Hold?
BioCardia, Inc.
NASDAQ:BCDA
$0.802 USD
-$0.11 (-11.89%)
- Volume
- 745.18K
- Average Volume
- 3.15M
- Market Capitalization
- $4.65M
- P/E Ratio
- -0.78
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $2.42
- Year Low
- $0.78
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.41
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Peter A. Altman |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BCDA |
| CUSIP | 09060U606 |
| CIK | 0000925741 |
| Web | https://www.biocardia.com |
| Phone | 650 226 0120 |
| Currency | USD |
| Employees | 17 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.39 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.41 |
| Quick Ratio | 0.41 |
| Cash Ratio | 0.34 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.69 |
| Price / Cash Flow | -0.62 |
| Price / Book | -8.13 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.23 |
| Trailing P/E Ratio | -0.78 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | $-8.23M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -5456.14% |
| Return on Assets | -454.15% |
Financials Score
| AltmanZ Score | -154.65 |
| Piotroski Score | 2.00 |
| Working Capital | -1.64M |
| Total Assets | 1.71M |
| Ebit | -7.78M |
| Market Cap | 4.65M |
| Total Liabilities | 2.78M |
Poll Results
About BioCardia, Inc. (NASDAQ:BCDA) Stock
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardi ... a also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
New Strong Sell Stocks for July 14th
2026-07-14 08:21:23
AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026.
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
2026-06-18 08:00:00
SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the Company's Chief Executive Officer, Peter Altman, issued the following letter to shareholders.
BioCardia Announces $4.4 Million Financing
2026-06-08 08:00:00
Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash runway would extend well beyond PMDA approval and into first commercial sales.
Why Is BioCardia Stock Gaining Friday?
2026-06-05 11:06:19
BioCardia Inc. (NASDAQ:BCDA) stock is up on Friday as the company is confirming progress toward potential market approval for its CardiAMP cell therapy.
2026-06-05 08:00:00
SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its Q-Sub Meeting with FDA Center for Biologics Evaluation and Research (CBER) on the CardiAMP Cell Therapy System for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF).
2026-05-21 08:00:00
– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development – Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) preliminary open label cohort at EuroPCR, a leading interventional cardiovascular medicine conference held in Paris.
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
2026-05-15 18:20:41
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
2026-05-15 08:00:00
SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter 2026 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session.
Frequently Asked Questions
-
What is the current BioCardia, Inc. (BCDA) stock price?
-
BioCardia, Inc.(NASDAQ:BCDA) stock price is $0.802 in the last trading session. During the trading session, BCDA stock reached the peak price of $2.42 while $0.78 was the lowest point it dropped to. The percentage change in BCDA stock occurred in the recent session was --11.89% while the dollar amount for the price change in BCDA stock was -$-0.11.
-
BCDA's industry and sector of operation?
-
The NASDAQ listed BCDA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BCDA?
-
David McClung | Chief Financial Officer
Miranda Peto Benvenuti | Investor Relations Executive
Peter A. Altman | Chief Executive Officer, President & Director
Edward Gillis | Senior Vice President of Devices
| -
How many employees does BCDA have?
-
Number of BCDA employees currently stands at 17. BCDA operates from 320 Soquel Way, Sunnyvale, CA 94085, US.
-
Link for BCDA official website?
-
Official Website of BCDA is: https://www.biocardia.com
-
How do I contact BCDA?
-
BCDA could be contacted at phone #650 226 0120 and can also be accessed through its website. BCDA operates from 320 Soquel Way, Sunnyvale, CA 94085, US.
-
How many shares of BCDA are traded daily?
-
The average number of BCDA shares traded daily for last 3 months was 3.15M.
-
What is the market cap of BCDA currently?
-
The market value of BCDA currently stands at $4.65M with its latest stock price at $0.802